PolicyWinds
Topic and direction labels are AI-assisted, and each one quotes the bill text it is based on. How labels work
Texas · 89th Legislature Regular Session

HB2585 Relating to the capacity of minors to consent to contraception-related examination or medical treatment.

Direction

Abortion otherAI label

Expands abortion access model confidence 80%

Adds capacity for minors to consent to contraception-related examination or medical treatment (other than abortion), expanding access to contraception services for minors without parental consent.

(8) consents to a contraception-related examination or medical treatment, other than abortion.

✓ Quote verified word for word in the bill text

Abortion personhood ivfAI label

No change to abortion access model confidence 90%

The bill defines 'contraception' as reversible methods approved by the FDA and explicitly excludes abortion from the new consent provision, but does not define an unborn child, grant legal rights to the unborn, or address fetal personhood or IVF.

In this section, "contraception" means any reversible method of preventing pregnancy that is approved by the United States Food and Drug Administration.

✓ Quote verified word for word in the bill text

  1. Filed (completed)
  2. Committee
  3. Passed one chamber
  4. Passed both
  5. Governor
  6. Law

Status: Died (session ended)

Last action
2025-03-17: Referred to Public Health
Filed
2025-02-07
Committee
Public Health
Sponsor
Ana-Maria Rodriguez Ramos D

Why the model tagged it this way: The bill amends Texas Family Code to allow minors to consent to contraception-related care (other than abortion), which expands access to contraception. It carves out abortion explicitly and defines contraception narrowly as reversible FDA-approved methods, but contains no provisions on abortion bans, gestational limits, funding, personhood, or IVF that would affect the abortion axis.

Related bills

Sponsors

Text versions

History (3 actions)
DateChamberAction
2025-03-17HReferred to Public Health
2025-03-17HRead first time
2025-02-07HFiled